home / stock / bcda / bcda news

BCDA News and Press, BioCardia Inc. From 11/09/22

Stock Information
Company Name: BioCardia Inc.
Stock Symbol: BCDA
Market: NASDAQ
Website: biocardia.com
Menu
BCDA BCDA Quote BCDA Short BCDA News BCDA Articles BCDA Message Board
Get BCDA Alerts

News, Short Squeeze, Breakout and More Instantly...
BCDA - BioCardia GAAP EPS of -$0.17, revenue of $0.21M

BioCardia press release ( NASDAQ: BCDA ): Q3 GAAP EPS of -$0.17. Revenue of $0.21M (-74.4% Y/Y). For further details see: BioCardia GAAP EPS of -$0.17, revenue of $0.21M

BCDA - BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly re...

BCDA - BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine m...

BCDA - BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough CardiAMP® Cell...
BCDA - CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting

Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that new data from its CardiAMP® Cell Therapy for H...

BCDA - BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.  The conference is being held on September 12-14, 2022. The in-person ...

BCDA - BioCardia to Participate in Cantor Fitzgerald's Cell and Genetic Medicines Conference

SUNNYVALE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced it will participate on a panel as a presenting company at Cantor Fitzgerald’s Cell and Genetic Medicines Conference. The conference is being held in person on Se...
BCDA - BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Adaptive Statistical Analysis Plan Recommended SUNNYVALE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the ind...

BCDA - BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

BioCardia ( NASDAQ: BCDA ) signed an agreement to provide its catheter biotherapeutic delivery product candidates for BlueRock Therapeutics' cell therapy products to treat heart failure. Under the agreement, BioCardia will receive an upfront payment, a portion of which...

BCDA - BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock's Cell Therapy to Treat Heart Failure

SUNNYVALE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock’s cell therapy product candidates for the treatment of heart failure u...
Previous 10 Next 10